Harlan CRS and Bertin Pharma Sign Strategic Collaboration Agreement
Complete the form below to unlock access to ALL audio articles.
Harlan Contract Research Services and Bertin Pharma have announced a strategic partnership to offer a comprehensive package for early drug development.
Under the agreement, the companies will offer a wider range of drug discovery and translational medicine services, including expanded profiling and molecule testing, especially in the context of regulatory studies.
Through the alliance, Harlan CRS will strengthen its drug discovery and translational medicine offerings utilizing Bertin Pharma’s expertise in immunology and biomarkers.
“We welcome this strategic agreement with Bertin Pharma. Its expertise in the immunological sector is impressive and well-known in the industry,” said Manuela Leone, president of Harlan CRS.
“The new agreement benefits us both strategically and scientifically,” said Ciriaco Maraschiello, director of strategic initiatives and director of drug discovery and translational medicine at Harlan CRS. “Working together, we will provide the pharmaceutical industry the best team of scientists to increase the likelihood of success for new generation drugs.”
“For Bertin Pharma, this partnership will increase our international visibility and allow us to expand our services by integrating project management capabilities and expertise,” said Xavier Morge, managing director of Bertin Pharma.
“PharmImmune, our joint offer with the French Alternative Energies and Atomic Energy Commission (CEA), is the perfect example of an innovative tool that we will be able to better utilize through our agreement with Harlan CRS,” said Pascal Clayette, head of the immuno-pharmacology department at Bertin Pharma.
